Skip to main content
Top
Published in: Journal of Gastroenterology 3/2016

01-03-2016 | Original Article—Liver, Pancreas, and Biliary Tract

Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing

Authors: Yoshihito Uchida, Jun-ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Satsuki Ando, Masamitsu Nakao, Daisuke Motoya, Mie Inao, Yukinori Imai, Nobuaki Nakayama, Satoshi Mochida

Published in: Journal of Gastroenterology | Issue 3/2016

Login to get access

Abstract

Background

Dual oral therapy with daclatasvir plus asunaprevir yielded an SVR rate of 85 % among patients with genotype 1b HCV. Treatment failure mainly occurred in patients with pre-existing HCV with NS5A-Y93H mutation. The significance of the mutation was evaluated.

Methods

The percent of serum NS5A-Y93H strains relative to the total strains was quantified using cycling-probe real-time PCR combined with direct sequencing in 444 patients with genotype 1b HCV, and the factors associated with mutation were analyzed. The mutation rates during interferon therapy were measured sequentially.

Results

NS5A-Y93H strains (1–100 % of the total strains) were detected in 87 patients (19.6 %). Mutant strains were detected more frequently among women than among men, in patients with a favorable allele in the IL28B-related gene SNP than among those with unfavorable alleles, and among patients without HCC and/or with serum AFP levels less than 6.0 ng/ml than among those with HCC and/or levels of 6.0 ng/ml or more. A multivariate analysis revealed that IL28B-related gene polymorphisms were significant factors associated with mutant strains. Although the frequency of patients with mutant strains was equivalent among patients depending on their previous interferon therapies, a sequential analysis during the interferon administrations revealed that the mutant strains disappeared earlier than the wild-type strains.

Conclusions

NS5A-Y93H mutation was associated with sex, serum AFP levels, and IL28B-related gene polymorphisms in patients infected with genotype 1b HCV. The indications for NS5A inhibitor use should be determined based on these factors, since mutant strains seem to be sensitive to interferon.
Literature
1.
go back to reference Higuch M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis. 2002;55:69–77. Higuch M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis. 2002;55:69–77.
2.
go back to reference Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676–91.CrossRefPubMed Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676–91.CrossRefPubMed
3.
go back to reference Umemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl19):102–7.CrossRefPubMed Umemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl19):102–7.CrossRefPubMed
4.
go back to reference Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174–81.CrossRefPubMed Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174–81.CrossRefPubMed
5.
go back to reference Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.CrossRefPubMed Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78–84.CrossRefPubMed
6.
go back to reference Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134–42.PubMedCentralCrossRefPubMed Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134–42.PubMedCentralCrossRefPubMed
7.
go back to reference Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59:205–12.CrossRefPubMed Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59:205–12.CrossRefPubMed
8.
go back to reference Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1–12.PubMedCentralCrossRefPubMed Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1–12.PubMedCentralCrossRefPubMed
9.
go back to reference Sugawara K, Inao M, Nakayama N, et al. Telaprevir-induced, but not PEGylated interferon-associated, retinopathy as a noteworthy. J Gastroenterol. 2014;49:363–8.CrossRefPubMed Sugawara K, Inao M, Nakayama N, et al. Telaprevir-induced, but not PEGylated interferon-associated, retinopathy as a noteworthy. J Gastroenterol. 2014;49:363–8.CrossRefPubMed
10.
go back to reference Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:218–27.CrossRef Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:218–27.CrossRef
11.
go back to reference Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: The CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49:941–53.CrossRefPubMed Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: The CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49:941–53.CrossRefPubMed
12.
go back to reference Kumada H, Hayashi N, Izumi N, et al. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res. 2015;45:501–13.CrossRefPubMed Kumada H, Hayashi N, Izumi N, et al. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res. 2015;45:501–13.CrossRefPubMed
13.
go back to reference Hayashi N, Mobashery N, Izumi N. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. J Gastroenterol. 2015;50:238–48.PubMedCentralCrossRefPubMed Hayashi N, Mobashery N, Izumi N. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. J Gastroenterol. 2015;50:238–48.PubMedCentralCrossRefPubMed
14.
go back to reference Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655–62.CrossRefPubMed Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655–62.CrossRefPubMed
16.
go back to reference Sugawara K, Koushima Y, Inao M, et al. Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b HCV infection according to an algorithm based on the drug adherence, IL28B gene allele and viral response: the AG and RGT Trial. Hepatol Res. 2015;. doi:10.1111/hepr.12475 (In press). Sugawara K, Koushima Y, Inao M, et al. Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b HCV infection according to an algorithm based on the drug adherence, IL28B gene allele and viral response: the AG and RGT Trial. Hepatol Res. 2015;. doi:10.​1111/​hepr.​12475 (In press).
17.
go back to reference Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646–54.CrossRefPubMed Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646–54.CrossRefPubMed
18.
go back to reference Uchida Y, Kouyama J, Naiki K, et al. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647.PubMedCentralCrossRefPubMed Uchida Y, Kouyama J, Naiki K, et al. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647.PubMedCentralCrossRefPubMed
19.
go back to reference Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372–80.CrossRefPubMed Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372–80.CrossRefPubMed
20.
go back to reference Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to PEGylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Gent. 2009;41:1105–9.CrossRef Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to PEGylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Gent. 2009;41:1105–9.CrossRef
21.
go back to reference Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54:352–4.CrossRefPubMed Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54:352–4.CrossRefPubMed
22.
go back to reference Miura M, Maekawa S, Sato M, et al. Deep sequencing analysis of variant resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360–7.CrossRefPubMed Miura M, Maekawa S, Sato M, et al. Deep sequencing analysis of variant resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360–7.CrossRefPubMed
23.
go back to reference Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641–50.PubMedCentralCrossRefPubMed Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641–50.PubMedCentralCrossRefPubMed
24.
go back to reference Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92–100.CrossRefPubMed Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92–100.CrossRefPubMed
25.
go back to reference Asahina Y, Tsuchiya K, Nishimura T, et al. α-fetoprotein levels after interferon therapy and risk of hepatocellular carcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253–62.CrossRefPubMed Asahina Y, Tsuchiya K, Nishimura T, et al. α-fetoprotein levels after interferon therapy and risk of hepatocellular carcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253–62.CrossRefPubMed
26.
go back to reference Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065–7.CrossRefPubMed Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065–7.CrossRefPubMed
27.
go back to reference Akuta N, Suzuki F, Seko Y, et al. Complicated relationship of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology. 2012;46:2134–41.CrossRef Akuta N, Suzuki F, Seko Y, et al. Complicated relationship of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology. 2012;46:2134–41.CrossRef
28.
go back to reference Abe H, Ochi H, Maekawa T, et al. Common variation of IL28B affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53:439–43.CrossRefPubMed Abe H, Ochi H, Maekawa T, et al. Common variation of IL28B affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53:439–43.CrossRefPubMed
29.
go back to reference Kobayashi M, Suzuki F, Akuta N, et al. Association of the polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol. 2012;47:596–605.CrossRefPubMed Kobayashi M, Suzuki F, Akuta N, et al. Association of the polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol. 2012;47:596–605.CrossRefPubMed
Metadata
Title
Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing
Authors
Yoshihito Uchida
Jun-ichi Kouyama
Kayoko Naiki
Kayoko Sugawara
Satsuki Ando
Masamitsu Nakao
Daisuke Motoya
Mie Inao
Yukinori Imai
Nobuaki Nakayama
Satoshi Mochida
Publication date
01-03-2016
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 3/2016
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-015-1106-8

Other articles of this Issue 3/2016

Journal of Gastroenterology 3/2016 Go to the issue